Treatment Trials

4 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      Technology-Enhanced Executive Functioning Intervention for ADHD
      Description

      This study develops and refines an online platform that will support clinician-directed behavioral and organizational skills intervention for adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) with input guided from key stakeholders during focus groups and interviews (phase 1), extended usability testing (phase 2), and a pilot randomized trial (phase 3) of the online tool used in conjunction with an organizational skills intervention.

      Conditions
      ADHDAttention Deficit Hyperactivity DisorderAttention Deficit DisorderADDADHD Predominantly Inattentive TypeADHD - Combined TypeADHD, Predominantly Hyperactive - ImpulsiveAttention-Deficit Disorder in AdolescenceAttention-Deficit Hyperactivity Disorder SymptomsAttention-Deficit Hyperactivity Disorder
      Talk to us
      UNKNOWN
      Ocular-vestibular Biomarker Identification for ADHD
      Description

      This study intends to establish a relationship between oculovestibular eye tracking measures, measures of ADHD, and medication prescribed for ADHD.

      Conditions
      ADHD - Combined TypeADHDADHD Predominantly Inattentive TypeADHD, Predominantly Hyperactive - Impulsive
      Talk to us
      COMPLETED
      Effectiveness of a Behavioral Treatment Program for Attention Deficit Hyperactivity Disorder, Inattentive Type
      Description

      This study will test the effectiveness of a new behavioral treatment, called the Child Life and Attention Skills Program, for children with attention deficit hyperactivity disorder, inattentive type.

      Conditions
      Attention Deficit Disorder With Hyperactivity
      Talk to us
      COMPLETED
      A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
      Description

      This study is a multisite, randomized, double-blind, placebo-controlled, phase 2/3 study of MG01CI (1400 mg daily) for 6 weeks compared with placebo in a 1:1 ratio of 300 adults with ADHD.

      Conditions
      ADHDAttention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type
      Talk to us